Stock Analysis

Oceania Healthcare Full Year 2024 Earnings: Misses Expectations

NZSE:OCA
Source: Shutterstock

Oceania Healthcare (NZSE:OCA) Full Year 2024 Results

Key Financial Results

  • Revenue: NZ$274.6m (up 11% from FY 2023).
  • Net income: NZ$31.5m (up 104% from FY 2023).
  • Profit margin: 12% (up from 6.2% in FY 2023).
  • EPS: NZ$0.044 (up from NZ$0.022 in FY 2023).
earnings-and-revenue-growth
NZSE:OCA Earnings and Revenue Growth May 25th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Oceania Healthcare Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 7.5%. Earnings per share (EPS) also missed analyst estimates by 51%.

Looking ahead, revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in New Zealand.

Performance of the New Zealander Healthcare industry.

The company's shares are up 1.8% from a week ago.

Risk Analysis

We should say that we've discovered 2 warning signs for Oceania Healthcare (1 makes us a bit uncomfortable!) that you should be aware of before investing here.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.